Shanghai Yizhong Pharmaceutical Co Ltd Sustainability Reports
The company develops and commercializes innovative nano-drug delivery systems and new dosage forms for anti-tumor therapies. Its primary approved product is a paclitaxel polymer micelle injection used for treating non-small cell lung cancer and other malignant tumors.
Sector: Manufacturing
Country: China
Exchange: Shanghai Stock Exchange
FIGI: BBG00BS17C44
1 reports from 2024 to 2024